logo-loader
viewMoneysupermarket.com

Moneysupermarket share price slashed as growth compares badly

Growth at the deals website appears to be slowing, after a thriving first half of the year with growth at 17%

Moneysupermarket.com -

Moneysupermarket.com Group PLC’s (LON:MONY) shares were in the bargain basement after growth slowed in its latest quarter.

The price comparison website posted 4% higher revenues of £100.9mln in the three months to September, but that compared badly with the 15% and 19% growth seen in the previous two quarters.

The main sticking point was its Money division, which represents a fifth of the company’s total revenues and saw revenues drop 5% to £20.6mln.

Money will weaken further in the last quarter, the comparison site warned.

Energy switching remained solid due to the great provider offers and large customer savings.

Moneysupermarket’s chief executive Mark Lewis said: "The group continued to grow in the quarter, with strong trading in energy showing that there are still big savings to be made by customers even though the price cap is lower.”

Broker Liberum said that the group's weaker performance in money and insurance should be attributed to "subdued market conditions as opposed to Moneysupermarket’s competitive position within price comparison", adding that Moneysupermarket's new strategy is a "fundamental game changer", using first party data to push personalised deals to consumers.

The website is in the second year of its so-called ‘Reinvent’ strategy, which aims to personalise deals for customers, as well as offer new products such as mortgages.

Quick facts: Moneysupermarket.com

Price: 346.2 GBX

LSE:MONY
Market: LSE
Market Cap: £1.86 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma PLC's Lisa Anson updates on lead asset RXC004 and increased...

Redx Pharma PLC's (LON:REDX) Lisa Anson recaps on its lead product RXC004 which is in a Phase I clinical trial and is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors. Anson also details the recent investment by its majority shareholder Redmile which has...

11 hours, 53 minutes ago

2 min read